Importantly, the ligand inhibited c-MYC transcription and reduced cell viability in a panel of myeloma cell lines, whereas it exhibited minimal effects for a cell that harbors a c-MYC translocation, deleting the G4-forming element in the promoter and normal blood mononucleocytes. This evidence concerns the gene MYC and plasma cell myeloma.